1.
Wolfgang Lamm, Hannes Kaufmann, Markus Raderer, Martha Hoffmann, Andreas Chott, Christoph Zielinski, Johannes Drach. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. haematol [Internet]. 2011Jul.1 [cited 2022Sep.28];96(7):1008-14. Available from: https://haematologica.org/article/view/6008